علاج رقاص سيدنهام المعتدل إلى الشديد مع الإعاقة الوظيفية (mRS 2–5)

References

• Patients with moderate and severe SC should be offered immunotherapy.
• Motor with/without behavioral or psychiatric symptoms with impact to activities of daily living, school and family life but not fulfilling criteria as in Severe Disease below.
• Symptomatic pharmacotherapy for movement disorder should be offered to all children with moderate to severe SC, in addition to antibiotics and immunotherapy.
• A lack of functional recovery (chorea or behavioral/psychiatric symptoms remain intrusive or disabling) after 2–4 weeks of treatment initiation is appropriate for considering failure to respond to treatment, and for potential treatment escalation. This period can be shorter for patients with severe SC.
• Immunotherapy will likely shorten the duration of chorea at the first episode of SC.

DOI: 10.1542/peds.2025-072466